J
2024
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
ŽÁČKOVÁ, Daniela; Lukáš SEMERÁD; Edgar FABER; Hana KLAMOVÁ; Lukáš STEJSKAL et. al.
Basic information
Original name
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF
Authors
ŽÁČKOVÁ, Daniela (203 Czech Republic, belonging to the institution); Lukáš SEMERÁD (203 Czech Republic, belonging to the institution); Edgar FABER (703 Slovakia); Hana KLAMOVÁ (203 Czech Republic); Lukáš STEJSKAL (203 Czech Republic); Petra BĚLOHLÁVKOVÁ (203 Czech Republic); Michal KARAS (203 Czech Republic); Eduard CMUNT (203 Czech Republic); Olga ČERNÁ (203 Czech Republic); Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution); Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution); Anežka KVETKOVÁ (703 Slovakia, belonging to the institution); Tomáš HORŇÁK (703 Slovakia, belonging to the institution); Ivana SKOUMALOVÁ (203 Czech Republic); Dana SRBOVÁ (203 Czech Republic); Cyril ŠÁLEK (203 Czech Republic); David BUFFA (203 Czech Republic); Jaroslava VOGLOVÁ (203 Czech Republic); Tomáš JURČEK (203 Czech Republic, belonging to the institution); Adam FOLTA (203 Czech Republic); Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution); Hana ŽIŽKOVÁ (203 Czech Republic); Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic); Tomáš PAPAJÍK (203 Czech Republic); Pavel ŽÁK (203 Czech Republic); Pavel JINDRA (203 Czech Republic); Adam SVOBODNÍK (203 Czech Republic, belonging to the institution); Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)
Edition
Leukemia, London, Nature Publishing Group, 2024, 0887-6924
Other information
Type of outcome
Article in a journal
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
is not subject to a state or trade secret
RIV identification code
RIV/00216224:14110/24:00135728
Organization
Lékařská fakulta – Repository – Repository
EID Scopus
2-s2.0-85187412156
Keywords in English
chronic myeloid leukemia; tyrosine kinase inhibitor
Links
LX22NPO5102, research and development project. NU22-03-00136, research and development project. CZECRIN IV, large research infrastructures.
V originále
Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR; i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale); however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment; furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation.
Displayed: 16/7/2025 21:06